NASDAQ : PPCB
Propanc Biopharma, Inc. — Key statistics
Healthcare · Biotechnology · Australia
Last price 1.84 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.16M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.22M |
| Enterprise Value | 897,495 |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 633,111 |
| Shares Outstanding | 633,111 |
| Shares Change (YoY) | +607.94% |
| Shares Change (QoQ) | +187.37% |
| Owned by Insiders (%) | 53.99% |
| Owned by Institutions (%) | 1.07% |
| Float | 291,280 |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.06 |
| P/TBV Ratio | 0.12 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.55 |
| Quick Ratio | 0.25 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -42.24 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -161.86% |
| Return on Assets (ROA) | -70.14% |
| Return on Invested Capital (ROIC) | -88.99% |
| Return on Capital Employed (ROCE) | -192.94% |
| Weighted Average Cost of Capital (WACC) | 36.04% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$9.90M |
| Employee Count | 2 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 3.34 |
| 52-Week Price Change | -99.44% |
| 50-Day Moving Average | 6.72 |
| 200-Day Moving Average | 23.44 |
| Relative Strength Index (RSI) | 21.16 |
| Average Volume (20 Days) | 47,012 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 50,470 |
| Short Previous Month | 71,162 |
| Short % of Shares Out | 7.97% |
| Short % of Float | 17.33% |
| Short Ratio (days to cover) | 0.16 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -18.19M |
| Pretax Income | -18.86M |
| Net Income | -19.79M |
| EBITDA | -18.18M |
| EBIT | -18.19M |
| Earnings Per Share (EPS) | -$176.16 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 832,006 |
| Total Debt | 509,116 |
| Net Cash | 322,890 |
| Net Cash Per Share | $0.51 |
| Equity (Book Value) | 9.40M |
| Book Value Per Share | 28.40 |
| Working Capital | 5.19M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -5.68M |
| Capital Expenditures | -4,933 |
| Depreciation & Amortization | 997 |
| Net Borrowing | -807,259 |
| Free Cash Flow | -5.69M |
| FCF Per Share | -$8.98 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -607.94% |
| Shareholder Yield | -607.94% |
| Earnings Yield | -9,138.68% |
| FCF Yield | -488.24% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Oct 26, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |